Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?
Mir
Olivier
O
Mouthon
Luc
L
Alexandre
Jérôme
J
Mallion
Jean-Michel
JM
Deray
Gilbert
G
Guillevin
Loïc
L
Goldwasser
François
F
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D050197:Atherosclerosis / Q000150:complications; D000068258:Bevacizumab; D017700:Embolism, Cholesterol / Q000139:chemically induced / Q000209:etiology*; D004802:Eosinophilia / Q000150:complications*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000150:complications; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D011446:Prospective Studies; D013577:Syndrome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab